Hyperlipidemia of the Type with Phlegm-Turbidity Obstruction
Conditions
Interventions
Treatment Group:Atorvastatin Calcium 20mg.qn combined with Ganoderma Spore Powder 2g per dose BID (twice daily)
Control Group:Atorvastatin Calcium 20mg.qn combined with placebo
Sponsors
Zhejiang Hospital
Eligibility
Sex/Gender
All
Age
40 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Meets the diagnostic criteria for hyperlipidemia as outlined in the "Chinese Guidelines for the Prevention and Treatment of Dyslipidemia in Adults" (2016 revised edition). Under normal dietary conditions the lipid test report shows one or more of the following conditions: total cholesterol (TC) = 6.2 mmol/L triglycerides (TG) = 2.3 mmol/L high-density lipoprotein (HDL-C) = 0.91 mmol/L low-density lipoprotein (LDL-C) = 3.4 mmol/L. Additionally the condition should be classified as hypercholesterolemia or mixed hyperlipidemia. 2. The traditional Chinese medicine (TCM) syndrome type is phlegm-dampness obstruction. 3. Age = 40 years old. 4. If the patient has previously taken lipid-lowering medications they should have stopped the medication for more than 4 weeks and their lipid levels should still meet the diagnostic criteria. 5. Voluntary participation in this research project with signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with simple hypertriglyceridemia or low high-density lipoprotein cholesterol (HDL-C); 2. Patients with critical conditions such as acute coronary syndrome acute cerebrovascular accident hypertensive crisis hypertensive encephalopathy or diabetic ketoacidosis; 3. Patients with end-stage diseases such as malignant tumors and an expected lifespan of less than 6 months; 4. Patients with hepatic or renal dysfunction: AST or ALT levels exceeding twice the upper limit of normal active liver disease or chronic kidney disease (CKD) stage 3 or above; 5. Pregnant women postpartum women lactating women or women planning for pregnancy; 6. Patients with poor follow-up compliance or severe emotional or mental disorders that hinder cooperation; 7. Patients participating in other clinical studies that may influence the outcomes of this research.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lipid Profile Test;TCM Syndrome Score;blood lipid; | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood Viscosity Indicators;Electrocardiogram;Kidney Function;Complete Blood Count (CBC);Echocardiography;intestinal flora;Liver Function;Visual diagnosis;Liver Ultrasound;Blood Viscosity;Oral Microbiota; | — |
Countries
China
Contacts
Public ContactMinchun Yang
Zhejiang Hospital
Outcome results
None listed